An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer

Status:
Unknown status

Trial end date:
2007-03-01

Target enrollment:

Participant gender:

The primary objectives of this study are to identify the maximum tolerated dose and to evaluate safety of atiprimod in patients with advanced cancer.

Phase 1/Phase 2

Callisto Pharmaceuticals